MedPath

To find whether Romiplostim is useful in Aplastic anemia treatment

Phase 3
Conditions
Health Condition 1: D619- Aplastic anemia, unspecified
Registration Number
CTRI/2023/09/057791
Lead Sponsor
Government of Uttar Pradesh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Confirmed cases of Aplastic anemia

2. Patient age >15years

3. Not willing for ASCT and ATG.

4. Non- pregnant women.

5. Those who consent to take part in the study.

6. No hepatic or renal disease.

7. No drug h/o that causes Myelo-suppression.

Exclusion Criteria

1. Previous history of HSCT,

2. Patients eligible for HSCT

3. Patients with HIV/ HCV/ HBV infections.

4. Significant PNH clone and Myelodysplasia.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Complete response (CR) defined as—transfusion independent, <br/ ><br>2.Non-responders will be transfusion-dependent <br/ ><br>Timepoint: 3months and 6 months
Secondary Outcome Measures
NameTimeMethod
1.Hemoglobin =11 g/dL, Absolute neutrophil count (ANC) more than 1.5 x 10 9 /L and platelet =150 x 10 9 /L; <br/ ><br>2.Partial response (PR) will be those who are transfusion independent, hemoglobin =8 g/dL, ANC more than 0.5 x 10 9 /L and platelet =20 x 10 9 /L <br/ ><br>Timepoint: 3months and 6months
© Copyright 2025. All Rights Reserved by MedPath